Previous Close | $0.27 |
AI Value | $64.95 |
Upside potential | +23,814% |
Biodesix, Inc. is a data-driven diagnostic solutions company focused on lung disease, particularly lung cancer. The company operates at the intersection of diagnostics and artificial intelligence, leveraging proprietary multi-omics and machine learning platforms to develop blood-based tests. Its flagship products include the Nodify Lung® nodule risk assessment tests and the GeneStrat® targeted mutation test, which aid in early detection and personalized treatment decisions. Biodesix holds a niche position in the $3B+ lung cancer diagnostics market, competing with Guardant Health (GH) and Exact Sciences (EXAS) but differentiating through its AI-driven approach and focus on pulmonary nodules. The company has established reimbursement coverage with Medicare and private payers for several tests, creating a recurring revenue stream.
Proprietary Proteograph™ platform analyzing >20,000 protein features per sample. 14 issued patents with 38 pending. Pipeline includes early-stage tests for COPD and ILD. AI algorithm trained on >250,000 patient datasets.
Biodesix presents a high-risk, high-reward opportunity in specialized diagnostics. The company's differentiated lung nodule tests and AI platform provide competitive moats, but profitability remains 2-3 years away. Key upside drivers include expanded Medicare coverage and pharma partnerships, while reimbursement cuts or slower-than-expected test adoption pose material risks. Suitable for investors with 3-5 year horizon and 15%+ portfolio risk tolerance.
Company 10-Q/Q3 2023, CMS CLFS fee schedules, Grand View Research lung cancer Dx report, Biodesix investor presentations
Historical valuation data is not available at this time.